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a  b s t  r a c  t
Objectives: The course and  long-term  outcome  of pure membranous lupus  nephritis  (MLN)  are little
understood.  The  aims of this study are  to  evaluate  the  clinical  features, course, outcome  and  prognostic
indicators  in pure MLN  and to  determine  the  impact  of ethnicity and  the  type of health  insurance  on  the
course and  prognosis  of pure MLN.
Methods: We  conducted  a retrospective  review of medical  records of 150  patients  with  pure MLN  from
Spain  and the  USA.
Results:  Mean age was  34.2  ± 12.5  and 80% were  women.  Sixty-eight  percent of patients  had
nephrotic  syndrome  at diagnosis. The average  serum  creatinine  was  0.98  ± 0.78 mg/dl. Six percent of
patients died and  5.3%  developed  end-stage  renal  disease (ESRD). ESRD  was predicted by male  sex,
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hypertension,  dyslipidemia,  high  basal  24 h-proteinuria,  high  basal serum creatinine  and  a low  basal
creatinine  clearance.  Age, cardiac  insufficiency,  peripheral  artheriopathy,  hemodialysis  and  not  having
received mycophenolate  mofetil  or  antimalarials for  MLN  predicted  death.
Conclusions:  Pure  MLN  frequently presents  with  nephrotic  syndrome,  high  proteinuria  and normal  serum
creatinine.  Its prognosis  is  favourable  in maintaining  renal function  although  proteinuria  usually per-
sists over time.  Baseline cardiovascular disease  and not having  a health insurance  are  related  with  poor
prognosis.
©  2017  Elsevier Espan˜a, S.L.U. and Sociedad Espan˜ola  de  Reumatologı´a y Colegio  Mexicano  de
Reumatologı´a.  All  rights  reserved.
Nefritis  lúpica  membranosa  pura:  descripción  de una  cohorte  de  150 pacientes
y  revisión  de la  literatura
r  e  s u  m e  n
Objetivos:  Los  conocimientos  sobre el  curso  y  el  desenlace  a largo  plazo  de  la  nefritis  lúpica  membranosa
(NLM) pura  son  todavía  escasos. El  objetivo  de  este  estudio  es evaluar  las características  clínicas,  curso,
desenlace  e indicadores  pronósticos  de  la NLM y  determinar  el impacto de  la etnicidad  y tipo  de  cobertura
sanitaria en  el curso  y pronóstico de  la NLM.
Métodos: Se  realizó  una revisión  retrospectiva  de las  historias de  150 pacientes  con  NLM de  Espan˜a  y
Estados  Unidos.
Resultados:  La edad  media  fue  34,2 ± 12,5 y  el 80% eran  mujeres.  El  68%  de  los pacientes tenían  síndrome
nefrótico  al diagnóstico. La  creatinina  sérica media fue  0,98 ± 0,78 mg/dl. El  6% de  los  pacientes fallecieron
y el 5,3%  desarrollaron insuficiencia renal  terminal  (IRT).  El  sexo masculino,  la hipertensión,  la dislipemia,
la alta  proteinuria  basal, la alta  creatininemia y  un  aclaramiento de  creatinina  reducido  predijeron  el
desarrollo  de  IRT.  La edad, la insuficiencia  cardíaca, la  arteriopatía periférica, la hemodiálisis  y  el no haber
recibido micofenolato de mofetilo  o antimaláricos  predijeron  el  fallecimiento.
Conclusiones: La NLM pura  suele debutar  con  síndrome  nefrótico, alta  proteinuria  y  creatininemia normal.
Su  pronóstico es favourable  en  términos  de  mantenimiento  de  la función  renal  aunque  la proteinuria
habitualmente  persiste  durante el  seguimiento.  La enfermedad  cardiovascular basal y  no tener cobertura
sanitaria  se relacionan con  mal pronóstico.
© 2017  Elsevier  Espan˜a, S.L.U.
y  Sociedad  Espan˜ola  de  Reumatologı´a y  Colegio  Mexicano  de Reumatologı´a.  Todos  los  derechos  reservados.
Introduction
Over 50% of patients with systemic lupus erythematosus (SLE)
have clinically significant renal involvement during the course of
their disease. Approximately 8–20% of these are found on  renal
biopsy to have membranous lupus nephropathy (MLN).1,2 Pure
MLN has distinct histologic features compared to  proliferative
lupus nephritis.3 This difference is  reflected in the clinical presen-
tations of proliferative and membranous lupus nephritis, with the
former being dominated by  a  nephritic process whereas MLN is
characterised predominantly by  nephrotic syndrome.1,4,5
Few studies have addressed the course and outcome of
MLN directly,4,6–14 and their results are contrasting. Most of
our knowledge is derived from extrapolations of data of idio-
pathic membranous nephritis and/or proliferative lupus nephritis.
Research on MLN  frequency, natural history, prognosis and treat-
ment was further limited due to a lack of uniform definition over
the  past several decades, making it difficult to get consistent infor-
mation from the published literature about MLN.1
An Italian study15 has reported the outcome in 103 patients with
MLN, but a third of them had mixed forms. More recently, Mejía-
Vilet et al.13 have reported the results of a cohort of 60 Hispanic and
Mexican-mestizo patients with pure MLN  suggesting an impact of
ethnicity on the response to  different immunosuppressants (aza-
thioprine, cyclophosphamide or  mycophenolate).
Large cohorts of patients with pure MLN  are lacking, and to
date the influence of ethnicity and social conditions on pure MLN
outcome has rarely been studied.
The aims of the present study are  to evaluate the clinical fea-
tures, course, outcome and prognostic indicators in pure MLN  and
to explore the association of ethnicity, socio-economic level, coun-
try of residence and the type of health insurance with the course
and prognosis of pure MLN.
Methods
Patients
This multicentre, retrospective clinicopathologic study evalu-
ated 150 patients with biopsy-proven Class Va pure MLN  (modified
WHO classification) who underwent renal biopsies between 1978
and 2011 in  24 hospitals in Spain and 1 in the United States. With
the aim of gathering a large number of pure MLN patients and tak-
ing into account its low prevalence, we chose to include patients
diagnosed in  a broad temporal range and from different geograph-
ical areas. The registers of renal biopsies of each hospital were used
to identify eligible patients. Patients were included if they met  at
least 4 American College of Rheumatology criteria for SLE16,17 with
evidence of kidney involvement and biopsy-proven pure MLN.18
Mixed forms of MLN  were excluded. The start of the study for each
patient was the day of the renal biopsy diagnosed MLN. The end
of follow-up for each patient was the day of the last visit available
in the medical records. If the patient had been rebiopsied and the
histological class had changed, he/she was  then excluded from the
analysis. The end of follow-up was the day of the last visit available
in the clinical records by July 2011.
Ethical approval was obtained from the Hospital Universitario
Puerta de Hierro Majadahonda Ethics Committee in  Spain and the
Hospital for Joint Diseases Ethics Committee in  the USA.
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Baseline Assessment
Baseline clinical data included age, sex, ethnicity, weight, body
mass index, smoking status (current, ex, never), education (none,
primary school, high school, university) and type of health insur-
ance (none, public, private). The presence of a diagnosis of diabetes
mellitus, hypertension, infection by Hepatitis B Virus (HBV), Hep-
atitis C Virus (HCV), Human Immunodeficiency Virus (HIV) or
tuberculosis, liver disease, ischaemic cardiopathy, cardiac failure,
cerebrovascular arteriopathy, peripheral arteriopathy, neoplasm,
osteoporosis and depression in the clinical records, either previ-
ously or at the time of MLN  diagnosis, was also recorded. Moreover,
all  SLE clinical manifestations, classified by  organ and/or system,
at the time of MLN  diagnosis were also recorded as well as the
Systemic Lupus Erythematosus Disease Activity Index (SELENA-
SLEDAI). Information regarding the treatments received for SLE or
comorbidities was registered.
The following laboratory values at the time of biopsy were
analysed: complete blood count, erythrosedimentation rate (ESR),
C-reactive protein (CRP), serum creatinine, serum albumin, serum
cholesterol and triglycerides, 24-h proteinuria, urine sediment,
serum complement (C3 and C4), the value of serum antinuclear
antibody (ANA), the presence and level of serum antibodies to  dou-
ble stranded DNA (dsDNA), the presence of serum antibodies to
non-DNA nuclear and cytosolic antigens (Sm, nRNP, SSA, SSB), and
of antiphospholipid (aPL) antibodies (lupus anticoagulant and/or
anticardiolipine antibody and/or anti-2 glycoprotein I antibody).
Creatinine clearance was calculated using the Cockcroft and Gault
formula.
We recorded the presence of nephrotic syndrome at MLN
diagnosis defined as presentation with urine protein excretion
of 3 g/24 h or greater, serum hypoalbuminemia and lower limbs
oedema simultaneously.
At the end of the follow-up, the same parameters were tested
and recorded along with the date of the test. Treatment prescribed
just after the diagnosis of MLN  was recorded including cortico-
steroids, antimalarials, immunosuppressants (cyclophosphamide,
azathioprine, mofetil mycophenolate, methotrexate and rituximab
among other), adjuvant therapy (antihypertensive, hypolipidemic,
antiaggregant and anticoagulant drugs), plasmapheresis, dialysis
and renal transplant.
Study Outcomes
Major end points were either death or end-stage renal disease
(ESRD) requiring chronic renal replacement therapy (dialysis or
transplant). Secondary end points included 24 h-proteinuria under
0.5 g, 24 h-proteinuria under 1 g,  doubling of serum creatinine,
renal failure defined as serum creatinine ≥1.2 mg/dL, and hyperten-
sion defined as systolic blood pressure (BP) greater than 140 mm
Hg and/or diastolic BP greater than 90 mm  Hg.
Statistical Analysis
In order to know the general characteristics of both populations
(Spanish and North American), a descriptive statistical analysis
with the initial variables was undertaken. Measures of central ten-
dency and dispersion such as mean, median, standard deviation
and extreme values were used as descriptive statistics. Equality
of distributions was investigated using the Kolmogorov–Smirnov
test. Continuous data are presented as mean ±  standard deviation.
Student’s t-test or Mann–Whitney U-test were used for compari-
son of continuous variables and the Chi-square test for categorical
variables.
Multiple logistic regression analysis was conducted to estimate
the factors associated with the different outcomes, adjusting by
hospital, ethnicity, education level and type of health coverage.
Variables included in the model were selected using a  backward
elimination for variables with a P>.05. Crude odds ratios (ORs) with
95% confidence intervals (CIs) and P values based on two-sided X2
tests (continuous variables) or Fisher exact tests (categorical vari-
ables) were calculated for all possible predictive factors. All  the
comparisons were with bilateral contrasts with an established level
of statistic significance in  values ≤0.05.
Statistical Package for Social Sciences (SPSS) v14.0 software for
Windows was used for all statistical analysis.
Results
Comparison Between Both Cohorts
Of the 150 patients included in  the analysis, 48 were followed-
up in the Hospital for Joint Diseases of New York and 102 in the
rheumatology departments of 24 different hospitals in  Spain. The
clinical characteristics at MLN  presentation, administered treat-
ments at any point during the course of the disease and outcome
of both cohorts are displayed in Tables 1–3.  Statistically significant
differences between both cohorts were found regarding ethnicity
distribution, type of health coverage, SLE duration at MLN  diagno-
sis (longer for North Americans) and presentation with nephrotic
syndrome and high blood pressure (both more frequent among
North Americans). Of the laboratory values, Spaniards had a  lower
C4 and a  higher percentage of ANA antibodies positivity at MLN
diagnosis. SELENA-SLEDAI at the point of MLN  diagnosis was only
calculated for the Spanish cohort (12.5 ± 5.7), as was creatinine
clearance (97.2 ± 44.7 ml/min) since not all the individual com-
ponents of these indexes were available for the North-American
cohort.
In  terms of treatment received for MLN, oral steroids, antimalar-
ials, immunosuppressive therapy with azathioprine (AZA) and
cyclosporine (CsA), and adjuvant therapy with diuretics, antihyper-
tensive and antilipidemic drugs were more often used in  Spanish
patients. As a whole, 17% (26 patients) of the cohort were treated
only with steroids, 25%  (37 patients) received steroids and only
one immunosuppressant drug, and 70 patients (47%) received more
than one immunosuppressant plus steroids. Seventeen patients did
not receive oral steroids for MLN.
The overall group was followed up for more than 7.5 years. Mean
follow-up was longer for Spaniards (117 months vs 34  months for
USA patients). A significantly higher percentage of Spanish patients
achieved a final 24 h-proteinuria under 0.5 g,  meaning a better
prognosis. Furthermore, a  higher percentage of North-American
patients had hypertension and renal failure at the end of follow-up.
There were no  significant differences between the both  groups in
the percentage of patients who developed end-stage renal disease
or died.
Predictors of Renal Outcome
We looked for predictors of the different outcomes in  the entire
group. In terms of comorbidities, several cardiovascular conditions
including ischaemic cardiopathy (P=.001), cardiac failure (P=.013),
cerebrovascular (P=.012) and peripheral (P=.012) vascular disease,
were significantly associated with death. Patients who died were
older at MLN  diagnosis (P=.006). Hemodialysis (P=.03) and not
having received mofetil mycophenolate (P=.039) or hydroxichloro-
quine (P=.03) for MLN  predicted death.
ESRD was associated with male sex (P=.011), basal hypertension
(P=.005), dyslipidemia (P=.017), high basal 24 h-proteinuria (7.57
vs 4.47 g; P=.016), high basal serum creatinine (2.76 vs 0.91 mg/dl;
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Table  1
Baseline Characteristics of the Included Patients.
All  (150) Spain (102) NYC (48) P
Age at diagnosis, years 34.22 ± 12.49 33.46 ± 12.34 35.85 ± 12.78 .275
Sex,  % women 78.7 78.4 79.2 .550
Race  (Caucasian/Hispanic-Am/African descent/Asian/Other) 98/22/12/8/10 93/7/1/0/1 5/15/11/8/9 <.001
Health  coverage (public/private/no) 104/22/24 102/0/0 2/22/24 <.001
SLE  duration, months 46.47 ± 64.78 37.98 ± 61.23 68.15 ± 69.21 .012
Serum  creatinine, mg/dl 0.98 ± 0.78 0.89 ± 0.48 1.18 ± 1.20 .047
Proteinuria 24 h, g 4.64 ± 3.55 4.72 ± 3.74 4.47 ± 3.11 .695
Serum  albumin, g/dl 3.87 ± 5,47 4.30 ± 6.66 3.03 ± 0.82 .222
Nephrotic syndrome, n  patients (%) 93 (67.9) 56 (56.6) 37 (97.4) <.001
Antiphospholipid syndrome, n  patients (%) 14 (9.3) 11 (10.8) 3 (6.3) .793
Tobacco, n smokers (%)  50 (46.3) 44 (48.4) 6 (35.3) .269
Basal  HBP, n patients (%) 73 (52,1) 46 (46) 27 (67.5) .017
Diabetes  mellitus, n  patients (%)  9  (6.8) 5 (5.3) 4 (10.5) .232
Dyslipidemia, n patients (%)  53 (40.5) 42 (44.2) 11 (30.6) .110
White  blood cells/mmc 6628 ± 3310 6369 ± 3314 7254 ± 3254 .151
Lymphocytes, cells/mmc 1692 ± 1185 1680 ± 1126 1723 ± 1339 .858
Platelets/mmc 257,209 ± 84,186 251,602 ± 90,771 269,243 ± 67,416 .269
C3  75.65 ± 36.82 75.41 ±37.27 76.23 ± 36.20 .906
C4  16.29 ± 13.21 14.75 ± 11.56 19.92 ± 16.06 .038
Hypocomplementemia, n  patients (%)  86 (57.3) 58 (57) 28 (58) .865
Positive  ANA, n patients (%) 143 (95.3) 101 (99) 42 (87.5) .005
Positive  Anti-dsDNA, n  patients (%) 110 (73.3) 74 (72.5) 36 (75) .457
aPL  positivity, n patients (%)  32 (24.6) 26 (26.3) 6 (19.4) .300
Anti-Sm,  n patients (%) 36 (24) 24 (23.5) 12 (25) .840
Ant-Ro,  n patients (%) 38 (25.3) 27 (26.5) 11 (22.9) .691
Anti-RNP, n patients (%)  40 (26.7) 31 (30.4) 9 (18.8) .167
ESR,  mm 54.19 ± 35.95 51.08 ± 30.76 63.74 ± 48.08 .119
CRP,  mg/l 9.70 ± 26.52 6.73 ± 12.72 18.48 ± 47.85 .095
ACEI, angiotensin converting enzyme inhibitor; aPL, antiphospholipidic; ARB, angiotensin receptor blockers; CRP, C reactive protein; ESR, erythrosedimentation rate; ESRD,
end-stage renal disease; HBP, high blood pressure; MMF,  mophetil mycophenolate; SLE, systemic lupus erythematosus.
Table 2
Treatment Given for Membranous Lupus Nephritis.
Drug All  (150) Spain (102) NYC (48) P
Hydroxychloroquine, n  patients (%) 47 (31.3) 37  (36.3) 10 (20.8) .041
Chloroquine, n patients (%) 18 (12) 18  (17.6) 0  (0) .001
IV  Metilprednisolone, n  patients (%) 13 (8.7) 11  (10.8) 2  (4.2)  .150
Prednisone, n patients (%)  133 (88.7) 101 (99) 32  (66.7) <.001
Azathioprine, n patients (%)  47 (31.3) 40 (39.2) 7  (14.6) .002
MMF,  n patients (%) 66 (44) 43  (42.2) 23  (47.9) .313
Cyclophosphamide, n patients (%) 38 (25.3) 29  (28.4) 9  (18.8) .142
Cyclosporine, n patients (%) 20 (13.3) 19  (18.6) 1  (2.1)  .003
Tacrolimus, n patients (%) 5 (3.3) 4 (3.9) 1  (2.1)  .486
Plasmapheresis, n patients (%) 2 (1.3) 2 (2) 0  (0) .461
IV  Immunoglobulins, n  patients (%)  2 (1.3) 2 (2) 0  (0) .461
Rituximab, n patients (%) 5 (3.3) 2 (2) 3  (6.3)  .187
ACEI,  n patients (%) 69 (46) 47  (46.1) 22  (45.8) .559
ARB,  n patients (%) 30 (20) 25  (24.5) 5  (10.4) .033
Diuretics, n patients (%) 37 (24.7) 36  (35.3) 1  (2.1)  <.001
Statins,  n patients (%)  44 (29.3) 42  (41.2) 2  (4.2)  <.001
Antiaggregants, n patients (%) 22 (14.7) 19  (18.6) 3  (6.3)  .035
Anticoagulants, n patients (%) 11 (7.3) 9 (8.8) 2  (4.2)  .254
Hemodialysis, n patients (%) 6 (4) 5 (4.9) 1  (2.1)  .374
Peritoneal dialysis, n  patients (%) 1 (0.7) 0  (0)  1  (2.1)  .320
Kidney  Transplant, n  patients (%) 5 (3.3) 5 (4.9) 0  (0) .141
ACEI, angiotensin converting enzyme inhibitor; aPL, antiphospholipidic; ARB, angiotensin receptor blockers; CRP, C reactive protein; ESR, erythrosedimentation rate; ESRD,
end-stage renal disease; HBP, high blood pressure; MMF,  mophetil mycophenolate; SLE, systemic lupus erythematosus.
Table 3
Outcome of MLN  in the Entire Cohort.
All (150) Spain (102) NYC (48) P
Mean follow-up, months 91.18 ± 89.42 117.73 ± 95.03 34.77 ± 34.16 <.0001
Proteinuria 24 h < 0.5  g, n  patients (%) 82 (64.6) 65 (69.9) 17 (50) .032
Proteinuria 24 h < 1 g, n  patients (%) 91 (72.8) 67 (75.2) 24 (70.6) .525
Doubling creatinine, n patients (%) 11 (8.4) 8 (8.2) 3 (9.1)  .557
Renal failure (Creat ≥1.2), n patients (%) 21 (15.5) 12 (9.2) 9 (34.4) .01
ESRD, n patients (%) 8 (5.3) 6 (5.9) 2 (4.2)  .499
Final HBP, n patients (%)  51 (40.2) 29 (29.6) 22 (75.9) <.001
Death,  n patients (%) 9 (6) 8 (7.8) 1 (2.1)  .155
ACEI, angiotensin converting enzyme inhibitor; aPL, antiphospholipidic; ARB, angiotensin receptor blockers; CRP, C reactive protein; ESR, erythrosedimentation rate; ESRD,
end-stage renal disease; HBP, high blood pressure; MMF,  mophetil mycophenolate; SLE, systemic lupus erythematosus.
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P<.001), nephrotic syndrome (P=.041) and a low creatinine clear-
ance (37 vs 102 ml/min; P<.001).
Patients with final doubled creatinine had a  higher initial serum
creatinine (1.92 vs 0.86 mg/dl; P<.001) and a  lower creatinine
clearance (59 vs 102 ml/min; P=.016). Male sex (P<.001), basal
hypertension (P<.001) and some cardiovascular conditions such as
ischaemic cardiopathy (P=.02), chronic cardiopathy (P=.018) and
peripheral vascular disease (P=.039) were also associated with dou-
bling basal serum creatinine.
Lastly, female sex (P=.017), a low basal serum creatinine (0.85
vs 1.39 mg/dl; P=.001) and previous treatment with AZA (P=.03)
were predictors of a final proteinuria <1 g. Nevertheless, North-
American patients (P=.042), patients without a  Health insurance
(P=.031), those positive to anti-dsDNA (P=.047) or aPL (P=.026)
antibodies and those who had suffered a  previous venous throm-
bosis (P=.036) had less chances of achieving a  final proteinuria
<0.5 g.
Multivariable analysis showed that patients who finally
achieved a 24 h proteinuria <0.5 g,  had public health insurance
(odds ratio [OR] 2.2; 95% confidence interval [CI], 0.72–6.74;
P=.165), a lower basal serum creatinine (OR 0.57; 95% CI, 0.27–1.17;
P=.126) and had received AZA for the treatment of MLN  (OR 2.2, 95%
CI, 0.91–5.3; P=.011). A predictive model with these three variables
would have an accuracy of 0.67 and a  negative likelihood ratio (LR)
for achieving a  final proteinuria <0.5 g of 0.33.
Patients without leukopenia (OR  0.31; 95% CI, 0.11–0.87; P=.028)
and with high serum creatinine (OR 0.26; 95% CI, 0.09–0.81; P=.020)
at  the time of MLN  diagnosis had less chances of achieving a  final
24 h proteinuria <1 g. The model based in these two variables could
predict a final proteinuria <1 g with an accuracy of 0.77, a  positive
LR 2.1 and negative LR 0.34.
And men  (OR 6.53; 95% CI, 1.33–32.06; P=.021) with a  higher
basal serum creatinine (OR 3.23; 95% CI 0.97–10.69; P=.05) were
more likely to have doubling basal serum creatinine at the end
of the follow-up. This could be predicted with an accuracy of 0.8,
positive LR 13.5 and negative LR 0.73.
Multivariable analysis was not performed for death and ESRD
due to the scarce number of cases that achieved these outcomes in
our cohort.
Discussion
In this study, we retrospectively analysed the baseline and long-
term follow-up characteristics of a cohort of 150 patients with pure
MLN. Unlike many other studies, we excluded patients with mixed
forms of membranous nephritis. There are only a  few studies con-
cerning pure MLN, and the conclusions about the presentation and
natural course are unclear. This is possibly a consequence of the
difficulties to identify histologically pure forms of MLN  according
to  the different classifications and also of the limitations for the
follow-up given that an optimal treatment for this type of lupus
nephritis has not been established yet.  Making inferences about
pure MLN  from cohorts that include different subtypes of class V
lupus nephritis can be deceptive.10,19,20 To the best of our knowl-
edge, this is the largest cohort on pure membranous lupus nephritis
to be reported in the literature. It is also the first to compare two
large groups of patients with MLN  from different sociocultural sett-
ings.
It is noteworthy the high percentage of patients with positive
anti-dsDNA antibodies in our series (73.3% of patients). MLN  may
be present with many, few or no other clinical or  serologic manifes-
tation of SLE.21,22 Anti-dsDNA antibodies are highly specific of SLE
and their high prevalence in our cohort supports these were con-
firmed SLE diagnoses. This high percentage of anti-dsDNA positivity
is similar to other series.13
Patients’ characteristics at MLN  presentation in our cohort are in
agreement with those reported by other authors (Table 4). As in our
cohort, MLN  usually presents in women  in their fourth decade of life
and after a mean of four years after SLE diagnosis. Renal function is
usually preserved at the beginning; impairment has been reported
in  0–20% across different cohorts.6,8–11,19,20,23–28 Nephrotic pro-
teinuria is  found at diagnosis in a  variable proportion of  patients,
and it usually evolves favourably with low percentages of death
and/or ESRD at follow-up.13,22,24,27,29 The percentage of poor out-
comes does not seem to vary with the length of the follow-up, since
the renal survival is  similar independently of the follow-up of  the
cohort. What seems to adversely influence the outcome is  the pres-
ence and persistence of a  nephrotic syndrome and having mixed
proliferative lesions.4–6,8,9,30 In very old and short-term studies18,31
MLN  was felt to exhibit an indolent and relatively benign course.
However, subsequent long-term series have shown contrasting
data about the prognosis of this disorder. Baldwin et al.32 found
71% of their 24 MLN  patients to  be persistently nephrotic; 25% pro-
gressed to renal failure over a  period of 6 years. González-Dettoni
et al.33 observed one the highest percentages of ESRD amongst
published cohorts with 25% of their 16 patients after a  4.5 years
follow-up. In contrast, ours and other cohorts13,18,19,21 have found
a  lower rate of progression to ESRD (Table 4). Moreover, a  number
of recent cohorts have even reported no patients progressing to
ESRD.11,23,24,26,34 It is likely that different patient populations with
varying epidemiological features such as ethnicity and socioeco-
nomic level, different degrees of proteinuria and renal insufficiency,
differing histologic features of MLN  and diverse treatment proto-
cols may  account for these divergent results. Establishing these
differences was precisely one of the major points of our  comparison
study between two  international cohorts.
Some significant differences were found between our two
cohorts. The American cohort had higher poor prognostic indica-
tors than the Spanish cohort as a  higher percentage of  patients
had nephrotic syndrome, high blood pressure and impaired renal
function at disease presentation. SLE duration at MLN  diagnosis
was longer in  the American cohort. This needs to be cautiously
interpreted as it may  reflect a  more difficult access to health care
rather than a  milder disease in  this population. The two cohorts
were also quite different regarding the ethnic groups distribution.
The North-American group included mainly Hispanic-American
patients and patients of African descent whereas the majority of
the Spanish patients were Caucasian. Our multivariable analysis
did not show prognostic differences among the different ethnici-
ties, probably due to  the small number of patients of  some of the
ethnic groups in the sample. Nevertheless, it is  well established that
there are considerable racial differences in the prevalence, severity,
and prognosis of lupus nephritis.35,36 Patients of African descent are
more severely afflicted with SLE and have worse outcomes when
compared with Caucasian patients.36,37 The reported prevalence of
SLE is  seven to eight times higher in Afro-Caribbeans, and two to
four times higher in  Asians than in Caucasians, while biopsy-proven
lupus nephritis is 25 times more common in both these groups
compared with Caucasians.38,39 It  is also known that the response
to  therapy varies among different ethnicities.13 A higher rate of
response to  therapy has been described in Asiatic cohorts.40 On  the
other hand, Hispanics may  have a higher response to mycopheno-
late than to cyclophosphamide as induction therapy and a  lower
rate of relapses when they receive mycophenolate as a mainte-
nance treatment as compared with azathioprine.41–43
In addition to ethnicity, low socioeconomic status has also been
associated with progression of SLE, mainly through increased car-
diovascular risk.44 If we consider the type of health insurance
as a  proxy of the socioeconomic status for the North-American
cohort, it could explain why this cohort had a  more severe dis-
ease at presentation and a  poorer prognosis. Nevertheless, due to
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Table 4
Series of Membranous Lupus Nephritis.
Presentation Outcome
Study Department No.  (Pure
forms)
SLE duration
at diagnosis
(months)
Follow-up
(months)
Nephrotic
syndrome (%)
(or prot ≥3 g
where
indicated)
Impaired renal
function (%)
Renal failure
(%)
ESRD (%)  Death (%)
Our data Rheumatology 150 46 91 68 20 16 5  6
Mejía-Vilet, 201613 Nephrology 60 7 51 61.7 38.3 - 3.3  5
Okpechi,  201254 Nephrology 42  (9 mixed) Not reported Not reported Not reported:
54.8% oedema
and  31%
hypertension
Not reported 26.2% patients reached the composite end-point of death,
end-stage renal failure or persistent doubling of serum
creatinine
Moroni,  201215 Nephrology 67  53 177 45 (prot ≥3.5 g) 16  19 (serum
creatinine
>1.2 mg/dL and
creatinine
clearance
<60 mL/min)
7.5 (need of
dialysis
therapy)
7.5
Kasitanon,  200824 Rheumatology 10 63.7 28.4 30 (prot ≥3 g) 0 20 0  0
Sun,  200822 Nephrology 100 54.5 59.5 31 (prot ≥3 g) Not  reported Not reported 6  2
Pasten,  200525 Rheumatology
/Nephrology
33 20 63 (1–316) 33 (prot ≥3 g) 15  36 12  21
Mok,  200455 Rheumatology
(Open CT)
38 48.5 (+59) 90.4 ± 59 58 Not  reported Not reported Not  reported 0
Spetie,  200426 Internal
Medicine
(CT)
12 Not reported 16 ± 8 75 17  (Creat >  1.2) 8 (Creat >  1.2) 0  0
Mercadal, 200229 Nephrology 66  Not reported 83 64 Not  reported 20 (doubling
creatinine)
12 4.5
Tam,  200127 Medicine
(CT)
10 86 (+85) 36 80 (prot ≥3 g) 20 (>110, equiv
to 1.2)
14 14  0
Mok,  199956 Rheumatology 25  22 130.7 20 Not  reported Not reported 0  3
Moroni,  19986 Nephrology 19  (4 mixed) Not reported 114 ± 63 100 5 16 5  0
Sloan,  199657 Nephrology 36  Not reported 70 ± 64 Not reported Not  reported Not reported 14  8
Chan,  199523 Nephrology 6  Not reported 32.2 ± 4.5 83 (prot ≥3 g) 0  0  0  0
Bakir,  199458 Nephrology 22  (some
mixed)
Not reported 82 (28–252) % not reported
(Mean prot.
4.9  ±  4.2)
% not  reported
(Mean serum
creatinine
1.2 ± 0.7)
14 9  5
Radhakrishnan, 19948 Nephrology 10 (3 mixed) 32 29.7 (23–43) 90 10 20 10 0
Pasquali,  19939 Nephrology 26  21.4 (+25.7) 74 ± 46 50 0  (Creat > 1.5) 12 8  8
Moroni,  199234 Nephrology
(Open CT)
6  Not reported 132–276 67 (prot ≥3 g) 0  17 0  0
Adler,  199010 Medicine 7  25 (+12) 54 ± 19 Not reported 0  14 (Creat >  1.5) 14  14
Leaker,  198711 Nephrology 20 25 62 (6–240) 70 0  (Creat > 1.2) 15 0  10
Gonzalez-Dettoni,
198533
Nephrology 16  19.2 54 (1–139) 63 19  25 25  0
Schwartz, 198419 Medicine 9  Not reported 60 Not reported 11  110 0  0
Wang  198428 Medicine 13  24.4 69.4 23 8 0  0  23
Donadio,  197721 Nephrology 28  82 47 (2–120) 64 0  7 7  21
Creat, Creatinine (in mg/dl); CT, clinical trial;  Prot., 24  h-proteinuria (in g).
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the characteristics of the health system in Spain, which has uni-
versal health coverage, the type of health insurance cannot be
taken as indicative of socioeconomic status for this population. The
entire Spanish cohort had public health insurance whereas only
2 patients from the North-American cohort had this type of health
insurance. Furthermore, half the North-American cohort had no
health insurance at all. This fact may  have delayed the diagnosis
of MLN  in USA patients and also limited the therapeutic possibil-
ities influencing the control of the disease. We found significant
differences in the use of oral steroids and several immunosup-
pressants in favour of the Spanish cohort. Although there is no
standard immunosuppressive regimen for MLN, it is  known that
the addition of immunosuppressive drugs in  combination with
steroids may  improve renal survival.45 The wide variation of treat-
ment combinations in  our cohort did not  allow us to reach any
conclusion about the optimal regimen, however our data suggests
that an aggressive therapeutic approach influences the course of
the apparently benign MLN. Patients from the Spanish cohort, who
more often received immunosuppressive therapy, had a better
prognosis, reflected by  a  higher percentage of patients achieving
a  24 h-proteinuria under 0.5 g at the end of follow-up and lower
percentage of patients developing high blood pressure. In particu-
lar, there was a  notable difference in the use of cyclophosphamide
(28.4% of patients in  the Spanish cohort vs 18.8% in the American
cohort) and azathioprine (39.2% vs 14.6%) between the two cohorts.
It is likely that doctors in Spain prescribed immunosuppressants
more frequently trying to  avoid poor outcomes given that  these
treatments were easily available. Another explanation can be  that
these drugs were given to patients who either had relapses after
treatment with only corticosteroids or were steroid-dependent.
Significant differences were also found regarding the use of anti-
hypertensives, diuretics, statins and antiaggregants between both
groups since they were more commonly used to treat patients in the
Spanish cohort. Patients with MLN  are at increased risk not only for
ESRD but also cardiovascular complications45,46 and adjuvant ther-
apy has an impact on the MLN  prognosis.47 In fact, in  our study,
not only ESRD but also mortality was predicted mainly by car-
diovascular comorbidities such as cardiac insufficiency, ischaemic
cardiopathy and peripheral arteriopathy. Over the last few decades,
with the decrease of early mortality due to uncontrolled disease,
cardiovascular complications have emerged as important causes
for late mortality.48 Since vascular complications are also accel-
erated in patients with renal failure, the risk of cardiovascular
complications is compounded in patients with ESRD and SLE.49,50
Therefore, adjuvant therapy can have a  positive influence on prog-
nosis in patients with lupus nephritis.
We found significant differences in the time of follow-up. Span-
ish patients were followed three times longer than the USA cohort.
Despite this notable difference, overall, the outcome was better for
the Spanish cohort. It  is  possible that the USA cohort would have
had even a worse prognosis if having been followed up for almost
10 years as the Spanish one. Nevertheless, there is no evidence that
the length of follow-up conditions a  poorer prognosis as presenting
with nephrotic syndrome or having mixed lesions do.6,8,9
High basal proteinuria, as well as a high serum creatinine and
a low creatinine clearance were all predictors of ESRD. This means
that patients with a  more severe basal nephritis had more chances
of losing their renal function at follow-up. In the multivariable
analysis, we only identified a low baseline serum creatinine and
having health insurance as predictors of good prognosis in terms
of achieving a  24 h-proteinuria under 0.5 g at the end of follow-up,
but it is possible that in  a larger sample factors such as ethnicity,
cardiovascular conditions or nephrotic syndrome are identified as
independent predictors. Nevertheless, no  major prognostic indica-
tors of MLN  renal survival emerges from the literature. Mercadal
et al.29 reported that a  profound initial hypoalbuminaemia was a
risk factor for ESRD and a sustained heavy proteinuria was  a  predic-
tor of doubling of the serum creatinine. However other authors18,51
have found no correlation between the degree of proteinuria
at the time of the renal biopsy and subsequent renal function
deterioration among patients with MLN. Austin et al.52 identified
proteinuria higher than 5 g/d and treatment with prednisone alone
as associated with a decreased probability of remission. Substan-
tial data has established the prognostic importance of  proteinuria
in various glomerular diseases including idiopathic membranous
nephropathy22,53 but it seems that in  membranous lupus nephritis
data are still contrasting.
Our study has several limitations. Although the Spanish MLN
patients are well represented in our  sample since they were fol-
lowed up at 24 different participating centres, all the patients from
the USA attended a  single centre in New York. It is probable that
this hospital does not represent the average standard of care in the
USA. Thus, although our results lack of generalizability, the compar-
ison between two  international cohorts represents a  strength as it
brings up some determinants of pure MLN  outcome not visible in
more homogeneous cohorts. Since our  aim was to make a  descrip-
tion of MLN  patients we did not record the date of events like death
or ESRD and subsequently could not perform a survival analysis.
The wide variety of therapies received by each patient prevented
us from evaluating the effectiveness of each single immunosupp-
ressant for pure MLN  since the final outcome of the disease could
not be associated with a specific drug. According to what has been
previously reported6,8,9 we do not  think that the difference in the
mean follow-up between the two cohorts influenced the results; in
any case, a  longer follow-up for the USA cohort would have made
the differences in  prognosis between cohorts more obvious so it
seems unlikely our  findings can be explained by the different length
of follow-up. A retrospective design is not the ideal methodology
for prognostic studies. Ideally, a  prospective study would identify
true prognostic factors for MLN. Despite this, the large number
of patients included in  this cohort would enable probable prog-
nostic factors to be studied in  greater detail in future prospective
cohorts. Furthermore, these preliminary results and our review of
the literature draw attention to the influence of different types of
health insurance and ethnicity in the prognosis of membranous
lupus nephritis.
Conclusion
MLN  usually begins with nephrotic syndrome, high proteinuria
and normal serum creatinine. Prognosis is favourable in  terms of
the maintenance of renal function, although proteinuria usually
persists over time. Patient and renal survival are high in patients
with pure types of MLN  but severity at presentation predicts a  poor
long-term outcome in terms of ESRD. Other factors such as baseline
cardiovascular disease and not having a health insurance are also
related with poor prognosis.
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